Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 19-Jun-2013
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 6 of 6)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
19-Jun-13ValuEngine, Inc.N/AValuEngine Industry Report for Medical-drugs18$207  View Abstract
14-Jun-13Ford Investor Services, Inc.N/AValue Graph: GALECTIN THERAP -- GALT1$11.50  View Abstract
14-Jun-13Ford Investor Services, Inc.N/AIndustry Value Graph: APRI , CORT , ELTP , GALT , MNOV , RGRX -- DRUGS3$34.50  View Abstract
13-Jun-13ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for GALT11$126.50  View Abstract
10-Jun-13Alpha Street ResearchHunter OrrGALT - Galectin Therapeutics Inc - Rated a Hold - Company Analysis and ASR Ranking Report9$24  View Abstract
23-May-13GlobalDataGlobalDataGalectin Therapeutics, Inc. (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile35$250  View Abstract
Independent Reports (Showing 1 to 6 of 6)
Release
Date [down]		 Contributor Author Title Pages Price More Info
19-Jun-13ValuEngine, Inc.N/AValuEngine Industry Report for Medical-drugs18$207View Abstract
14-Jun-13Ford Investor Services, Inc.N/AValue Graph: GALECTIN THERAP -- GALT1$11.50View Abstract
14-Jun-13Ford Investor Services, Inc.N/AIndustry Value Graph: APRI , CORT , ELTP , GALT , MNOV , RGRX -- DRUGS3$34.50View Abstract
13-Jun-13ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for GALT11$126.50View Abstract
10-Jun-13Alpha Street ResearchHunter OrrGALT - Galectin Therapeutics Inc - Rated a Hold - Company Analysis and ASR Ranking Report9$24View Abstract
23-May-13GlobalDataGlobalDataGalectin Therapeutics, Inc. (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile35$250View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.